CARDIFF ONCOLOGY, INC. Sublease Income
CARDIFF ONCOLOGY, INC. (CRDF) reported Sublease Income of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2023-03-02
- CARDIFF ONCOLOGY, INC. sublease income for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. sublease income for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. sublease income for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. sublease income for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. sublease income for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CARDIFF ONCOLOGY, INC. sublease income for fiscal 2021 was $403.00K, a 38.49% increase from fiscal 2020.
- CARDIFF ONCOLOGY, INC. sublease income for fiscal 2020 was $291.00K, a 23.75% decline from fiscal 2019.
- CARDIFF ONCOLOGY, INC. sublease income for fiscal 2019 was $381.65K.
| Period end | Sublease Income 3 month | Sublease Income 3 month as first filed | Sublease Income 6 month | Sublease Income 6 month as first filed | Sublease Income 9 month | Sublease Income 9 month as first filed | Sublease Income 12 month | Sublease Income 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $100.00K derived: sum of 4 quarters · filed 2023-03-02 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $100.00K derived: sum of 3 quarters · filed 2023-03-02 | $201.00K derived: sum of 4 quarters · filed 2023-03-02 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $100.00K derived: sum of 2 quarters · filed 2023-03-02 | $201.00K derived: sum of 3 quarters · filed 2023-03-02 | $302.00K derived: sum of 4 quarters · filed 2023-03-02 | ||||
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $201.00K derived: sum of 2 quarters · filed 2023-03-02 | $302.00K derived: sum of 3 quarters · filed 2023-03-02 | $403.00K 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | $101.00K 10-Q · filed 2022-11-03 | $202.00K derived: sum of 2 quarters · filed 2022-11-03 | $303.00K 10-Q · filed 2022-11-03 | $376.00K derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $101.00K 10-Q · filed 2022-08-04 | $202.00K 10-Q · filed 2022-08-04 | $275.00K derived: sum of 3 quarters · filed 2022-08-04 | $348.00K derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $101.00K 10-Q · filed 2022-05-05 | $174.00K derived: sum of 2 quarters · filed 2022-05-05 | $247.00K derived: sum of 3 quarters · filed 2022-05-05 | $320.00K derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $146.00K derived: sum of 2 quarters · filed 2022-02-24 | $219.00K derived: sum of 3 quarters · filed 2022-02-24 | $291.00K 10-K · filed 2022-02-24 | $291.17K 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $73.00K 10-Q · filed 2021-11-04 | $72.79K 10-Q · filed 2020-11-05 | $146.00K derived: sum of 2 quarters · filed 2021-11-04 | $218.00K 10-Q · filed 2021-11-04 | $218.38K 10-Q · filed 2020-11-05 | $300.84K derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $73.00K 10-Q · filed 2021-08-05 | $72.79K 10-Q · filed 2020-08-11 | $146.00K 10-Q · filed 2021-08-05 | $145.59K 10-Q · filed 2020-08-11 | $227.84K derived: sum of 3 quarters · filed 2021-08-05 | $327.78K derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $73.00K 10-Q · filed 2021-05-06 | $72.79K 10-Q · filed 2020-05-07 | $154.84K derived: sum of 2 quarters · filed 2021-05-06 | $254.78K derived: sum of 3 quarters · filed 2021-05-06 | $354.71K derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $81.84K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $181.78K derived: sum of 2 quarters · filed 2021-02-25 | $281.71K derived: sum of 3 quarters · filed 2021-02-25 | $381.65K 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $99.94K 10-Q · filed 2020-11-05 | $199.87K derived: sum of 2 quarters · filed 2020-11-05 | $299.81K 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $99.94K 10-Q · filed 2020-08-11 | $99.94K 10-Q · filed 2019-08-08 | $199.87K 10-Q · filed 2020-08-11 | $199.88K 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $99.94K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |